Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.

Author(s): Tsuji S, Kawano S, Higashi T, Mukuda T, Imaizumi T, Tatsumi T, Miura N, Miyajima K, Fukuda M, Noguchi M

Affiliation(s): First Department of Medicine, Osaka University School of Medicine, Japan.

Publication date & source: 1995, J Clin Gastroenterol., 20 Suppl 2:S1-4.

Publication type: Clinical Trial; Controlled Clinical Trial; Randomized Controlled Trial

We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer. Sixteen patients with active gastric ulcer were divided into two groups and received treatment with lansoprazole 30 mg/day or famotidine 40 mg/day. They were examined endoscopically at 2, 4, and 8 weeks to measure gastric bFGF levels at the ulcer margin and to assess ulcer healing. Helicobacter pylori infection was determined by a rapid urease test. The two groups were comparable with regard to age, male:female ratio, H. pylori infection rates, and bFGF levels. During treatment, bFGF levels did not change significantly in the famotidine group, whereas they increased by a factor of 2.2 to 2.6 in the lansoprazole group. Cumulative healing rates were also significantly lower in the famotidine group than in the lansoprazole group. These results indicate that lansoprazole increases tissue bFGF levels and promotes gastric ulcer healing in humans.